Navigation Links
Toward a more efficient therapy for a specific form of leukemia
Date:6/14/2011

Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML. Blocking this growth factor increases the life expectancy of these mice, even in those resistant to imatinib.

Chronic myeloid leukemia (CML)

In our body, white blood cells combat foreign intruders, such as viruses and bacteria. In chronic myeloid leukemia, the formation of granulocytes, a particular type of white blood cells, is disturbed. The cells in the bone marrow which should grow into white blood cells show an uncontrolled increase in numbers as a result of a disruption in the maturing process. This uncontrolled growth may damage various tissues and adversely affect the production of normal blood cells in the bone marrow. A shortage of white blood cells makes patients more susceptible to infection.

The Philadelphia chromosome and imatinib

Under normal circumstances, our body very accurately regulates the production of white blood cells. This process is triggered by targeted activation of tyrosine kinase. In most forms of CML, a deviant chromosome is present - the Philadelphia chromosome - which gives rise to BCR-ABL1 fusion kinase. This kinase causes the trouble, leading to the increase in CML cells. Existing medicines (imatinib) therefore target this kinase.

While the effect of imatinib in CML patients is usually quite favorable, the use of imatinib is often not sufficient to remove the diseased cells from the body. Sometimes the disease is already too advanced at the start of treatment, or there is resistance.

Placental growth factor

Researchers from the team headed by Peter Carmeliet have studied the role of placental growth factor (PlGF) in leukemia and the therapeutic potential of PIGF inhibitors. Recent research conducted by Peter Carmeliet had already shown that antibodies against PlGF (antiPlGF) can inhibit the growth of particular tumors.

The present study proves that PlGF also plays a role in CML. The researchers have recorded increased PIGF values in both mice and humans. It appears that PIGF does not only stimulate the division of CML cells but also encourages the formation of blood vessels in bone marrow. Finally, inhibiting PlGF in mice with CML leads to higher life expectancy, even in those mice that are resistant to the current medicine imatinib. All of these findings indicate that the therapeutic potential of PIGF inhibitors in CML needs to be investigated further.


'/>"/>

Contact: Evy Vierstraete
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related medicine news :

1. Attitudes toward end-of-life care: A survey of cancer patients and others in Korea
2. NIH grant for the move toward clinical trials targeting the lysosomal storage disease MPSIIIB
3. U.S. Pushes School Cafeterias Toward Healthier Offerings
4. Toward a vaccine for methamphetamine abuse
5. Negative attitudes toward fat bodies going global, study finds
6. Tiny gems take big step toward battling cancer
7. Top scientists unite to develop global scientific strategy Towards An HIV Cure
8. Toward a fast, simple test for detecting cholera rampaging in 40 countries
9. Major step taken toward an open and shared digital brain atlasing framework
10. Warning about benevolent sexism and mens apparently positive attitudes towards women
11. Early Steps Toward an Alzheimers Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... ... Dickinson Insurance & Financial Services continues their commitment to act as Agents ... local boy named Barrett, who has been fighting ALL leukemia for almost two years. ... all local families dealing with childhood cancer. Information on how to help is now ...
(Date:2/11/2016)... ... 2016 , ... Be Well Medical Group (Be Well) is pleased ... at 108 South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is ... the convenience of their homes, offices or at the practices’ local office. It is ...
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has completed ... CA, on February 6th & 7th, 2016 according to kicking coach Michael Husted. , ... invited to the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... in significantly higher rates of several common cancer screenings, especially among women. Cancer ... outcomes and survival rates. , The study,“What Does Medicaid Expansion Mean for ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the World Molecular Imaging Congress (WMIC), will be held in New York City, ... is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 http://www.researchandmarkets.com/research/rp4pg8/molecular ) ... "Molecular Diagnostics Reports Bundle" report to ... has announced the addition of the ... their offering. --> Research and ... addition of the "Molecular Diagnostics Reports ...
(Date:2/10/2016)... , Feb. 10, 2016  Fotona, based in the U.S. ... launch its new ST PRO Lightwalker dental laser at the ... Society from 25-27 February, 2016 in booth #4815. The ST ... laser with many of the features of the award winning, ... ST PRO competitive price will be very attractive to many ...
(Date:2/10/2016)... Feb. 10, 2016  Cepheid (Nasdaq: CPHD ... formerly Executive Vice President and Chief Operating Officer, ... and Chief Operating Officer.  In his new capacity, ... include Global Commercial Operations in addition to Manufacturing ... Kocmond will continue to report to John ...
Breaking Medicine Technology: